Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops
The purpose of this study is to evaluate the benefit of treatment of refractory Eustachian tube dysfunction with standard treatment for endolymphatic hydrops. Eustachian tube dysfunction is a common diagnosis made in otolaryngology related to abnormal pressure equalization of the middle ear space related to a swollen, inflamed, or occluded Eustachian tube. The symptoms of this include perceived hearing loss, a feeling of fullness in the affected ear/ears, ear pain, ear popping, and occasionally imbalance. These symptoms overlap with a more rare and difficult to diagnose condition known as endolymphatic hydrops, or an overproduction to fluid in the inner ear. The treatment for these two conditions are distinct and traditionally, patients are treated for Eustachian tube dysfunction first as it is much more common and there are several treatments, namely nasal steroids, antihistamines, and pressure equalization tubes. For patients who do not improve with these treatments, they are often treated with diuretics and a low salt diet to treat for supposed endolymphatic hydrops. There has never been a study to investigate the utility of these treatments in patients with refractory Eustachian tube dysfunction. There is also reason to believe that chronic ETD with effusion can lead to both inner and middle ear dysfunction. Thus, this study aims to determine the benefit of standard endolymphatic hydrops treatment on patient with refractory Eustachian tube dysfunction symptoms in a prospective fashion.
Patients with refractory Eustachian tube dysfunction (patients with no or minimal symptom improvement despite nasal steroid and antihistamine treatment followed by myringotomy tube placement) have an element of endolymphatic hydrops and these patient's symptoms will improve with a low sodium diet and diuretic.
Eustachian Tube Dysfunction
Drug: Nasal steroid
Procedure: Myringotomy tube placement
Behavioral: Low salt diet
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops?|
- Improvement in patient ETD symptoms with nasal steroid and antihistamine alone [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine the degree to which ETD symptoms are relieved with nasal steroid and antihistamine alone.
- Improvement in patient ETD symptoms with pressure equalization tubes [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine the degree to which patient's symptoms related to ETD improve after placement of pressure equalization tubes.
- Improvement in patients with refractory ETD symptoms with treatment for endolymphatic hydrops with a diuretic and low salt diet [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine the degree of improvement of patient symptoms in the setting of refractory ETD after a low salt diet and diuretic treatment.
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||August 2013|
|Estimated Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
Nasal steroid and Antihistamine
Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
|Drug: Nasal steroid Drug: Antihistamine|
Active Comparator: Myringotomy tubes
Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
|Procedure: Myringotomy tube placement|
Active Comparator: Low salt diet and diuretic
Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
|Drug: Diuretic Behavioral: Low salt diet|
Eustachian tube dysfunction is one of the most common problems encountered in general otolaryngology clinical practice. Symptoms of ear pressure, decreased hearing, ear pain, ear popping, and frequent ear infections are often blamed on the inability of the Eustachian tube to equalize air pressure across the ear drum. If the Eustachian tube is occluded, the middle ear space becomes a closed chamber in which normal gas exchange cannot occur. Treatment of Eustachian dysfunction has traditionally focused on a two tier system. First, patients are most often placed on a nasal steroid and an antihistamine. This medication regimen leads to decreased nasal inflammation, mucosal swelling, and treats nasal allergy. In many patients, this treatment improves symptoms completely or reduces them to a tolerable level. If the patient's symptoms are not improved, the next step in management is to create a surgical tract to the middle ear via a myringotomy (a hole across the ear drum) and placing a pressure equalization tube across the tympanic membrane. This bypasses any anatomical obstruction in the Eustachian tube and allows the middle ear pressure to equalize with the atmospheric pressure across the tympanic membrane. Unfortunately, despite this, there are patients with refractory symptoms, often ear pressure and subjectively decreased hearing. These symptoms are also frequently associated with inner ear disease, specifically endolymphatic hydrops. Endolymphatic hydrops is felt to be related to over production of endolymphatic fluid, the fluid within the inner ear. Thus, we propose that patient's will refractory Eustachian tube dysfunction are experiencing an inner ear phenomenon, and that they would benefit from treatment similar to how endolymphatic hydrops (or over production of endolymphatic fluid) is managed. The mainstays of management of endolymphatic hydrops are a low sodium diet and diuretic treatment (hydrochlorothiazide/triamterene). Both of these treatments aim to reduce endolymph production.
|Contact: James R Bekeny, MDemail@example.com|
|Contact: Georges Wanna, MDfirstname.lastname@example.org|
|United States, Tennessee|
|Vanderbilt University Medical Center--Division of Neurotology||Not yet recruiting|
|Nashville, Tennessee, United States, 37212|
|Contact: James Bekeny, MD 615-322-6180|
|Principal Investigator: George Wanna, MD|
|Sub-Investigator: James R Bekeny, MD|
|Sub-Investigator: Robert Labadie, MD|
|Sub-Investigator: Ken Watford, NP|
|Sub-Investigator: David Haynes, MD|
|Sub-Investigator: Marc Bennett, MD|
|Sub-Investigator: Alejandro Rivas, MD|